Literature DB >> 8258965

Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy.

G Cannella1, E Paoletti, R Delfino, G Peloso, S Molinari, G B Traverso.   

Abstract

There have been no studies of the possibility of reversing the left ventricular hypertrophy (LVH) of chronically hemodialyzed hypertensive uremics (HDH) with long-term antihypertensive therapy. We have measured left ventricular sizes of eight (6 male, 2 female, aged 29 to 61 years) HDH with M-mode echocardiography, before and 12, 18 and 24 months after the start of a combined antihypertensive therapy which included ACE-inhibitors, beta-blockers and calcium-antagonists. Pre-treatment values for mean blood pressure (MBP), 116.6 +/- 2.9 mm Hg, end diastolic diameter (EDD), 62.6 +/- 6.6 mm, interventricular septum (IVS), 14.2 +/- 3.0 mm, and left ventricular mass index (LVMi), 239 +/- 61 g/m2, were all significantly higher than those for nine sex- and age-matched hemodialyzed normotensive subjects (HDN) with comparable hemoglobin (Hb) levels. During the antihypertensive treatment, both the systolic and diastolic BP decreased steadily (P = 0.0001; P = 0.0003; ANOVA) and significantly by the third month (P < 0.05; P < 0.01), reaching levels comparable to those of the HDN group after 12 months. At this time the LVMi (204 +/- 67) and the IVS (13.1 +/- 2.7), although both significantly lower than baseline, were still higher than in the HDN group, while the EDD was similar. After 24 months, however, both the IVS (12.3 +/- 3.1) and the LVMi (161 +/- 65) were no longer different from those of the HDN group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258965     DOI: 10.1038/ki.1993.326

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

Review 1.  Current understanding of optimal blood pressure goals in dialysis patients.

Authors:  Paul Light
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

2.  Technical aspects of renal denervation in end-stage renal disease patients with challenging anatomy.

Authors:  Alessio Spinelli; Valerio Da Ros; Daniele Morosetti; Silvia D Onofrio; Valentina Rovella; Nicola Di Daniele; Giovanni Simonetti
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

3.  Probing dry-weight improves left ventricular mass index.

Authors:  Rajiv Agarwal; J Michael Bouldin; Robert P Light; Ashok Garg
Journal:  Am J Nephrol       Date:  2010-12-13       Impact factor: 3.754

Review 4.  Hypertension in hemodialysis patients.

Authors:  M Rahman; M C Smith
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

5.  Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease.

Authors:  C V Ram; P Vergne-Marini
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

6.  Antihypertensive treatment in patients with end-stage renal disease.

Authors:  Mensura Ascerić; Nedzad Mulabegović; Sabina Nuhbegović; Alma Nadarević; Muamera Mujcinagić-Vrabac
Journal:  Bosn J Basic Med Sci       Date:  2005-11       Impact factor: 3.363

7.  Left ventricular hypertrophy and risk factors for its development in uraemic patients.

Authors:  Senija Rasić; Indira Kulenović; Azra Haracić; Amra Catović
Journal:  Bosn J Basic Med Sci       Date:  2004-02       Impact factor: 3.363

Review 8.  Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis.

Authors:  Davina J Tai; Thomas W Lim; Matthew T James; Braden J Manns; Marcello Tonelli; Brenda R Hemmelgarn
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-04       Impact factor: 8.237

9.  Can losartan and blood pressure control peri arteriovenous fistula creation ameliorate the early associated left ventricular hypertrophic response a randomised placebo controlled trial.

Authors:  Dominica Zentner; Eugenie Pedagogos; Anthony Yapanis; Sofie Karapanagiotidis; Alison Kinghorn; Athanasia Alexiou; Geoffrey Lee; Matija Raspudic; Anuradha Aggarwal
Journal:  BMC Res Notes       Date:  2012-05-29

10.  Maxacalcitol (22-Oxacalcitriol (OCT)) Retards Progression of Left Ventricular Hypertrophy with Renal Dysfunction Through Inhibition of Calcineurin-NFAT Activity.

Authors:  Kazunori Inoue; Isao Matsui; Takayuki Hamano; Keiji Okuda; Yasumasa Tsukamoto; Ayumi Matsumoto; Karin Shimada; Seiichi Yasuda; Yusuke Katsuma; Yoshitsugu Takabatake; Masaru Tanaka; Noriko Tanaka; Toshiaki Mano; Tetsuo Minamino; Yasushi Sakata; Yoshitaka Isaka
Journal:  Cardiovasc Drugs Ther       Date:  2020-11-18       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.